Clinical Trials Arena
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
📈
AI Sentiment
Highly Positive
8/10
Novo Nordisk A/S News
Latest updates and market news for NVO
20 news
Dec 13 - Dec 19, 2025
Page 1
Investor's Business Daily
Eli Lilly, IBD Stock Of The Day, Proves The Merit Of Its Weight-Loss Pill
📈
AI Sentiment
Highly Positive
8/10
GuruFocus.com
Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound
📈
AI Sentiment
Highly Positive
9/10
Insider Monkey
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
📈
AI Sentiment
Highly Positive
9/10
Quartz
Lilly says obesity pill can replace shot after weight loss
📈
AI Sentiment
Highly Positive
9/10
Business Wire
Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role
📊
AI Sentiment
Positive
7/10
Investor's Business Daily
Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
Novo Nordisk (NVO) Fell Following a Profit Warning Release
➖
AI Sentiment
Neutral
4/10
The Wall Street Journal
Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Novo Nordisk Submits New Drug Application to FDA for CagriSema Weekly Weight-Loss Injection
📊
AI Sentiment
Positive
6/10
PR Newswire
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
📈
AI Sentiment
Highly Positive
10/10
Simply Wall St.
Novo Nordisk (NYSE:NVO): Reassessing Valuation After a Steep 1-Year Share Price Decline
📊
AI Sentiment
Positive
6/10
MT Newswires
Market Chatter: Eli Lilly and Company to Reduce Prices of its Diabetes, Weight-Loss Drugs in Canada by 20% or More
➖
AI Sentiment
Neutral
4/10
Business Wire
Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders
📈
AI Sentiment
Highly Positive
10/10
Zacks
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
📈
AI Sentiment
Highly Positive
8/10
Share this news page